Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/ALN.0000000000005522 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Antithrombin-binding heparan sulfate is ubiquitously expressed in epithelial cells and suppresses pancreatic tumorigenesis.
J Clin Invest
September 2025
Department of Cellular and Molecular Medicine, UCSD, La Jolla, United States of America.
3-O-sulfation of heparan sulfate (HS) is the key determinant for binding and activation of Antithrombin III (AT). This interaction is the basis of heparin treatment to prevent thrombotic events and excess coagulation. Antithrombin-binding HS (HSAT) is expressed in human tissues, but is thought to be expressed in the subendothelial space, mast cells, and follicular fluid.
View Article and Find Full Text PDFThromboelastography for the evaluation of coagulation function in patients with hepatic echinococcosis during the perioperative period: a retrospective study.
Front Oncol
August 2025
Department of Anesthesiology, Qinghai Provincial People's Hospital, Xining, China.
Objective: To study the application of thrombolysis diagram (TEG) and routine coagulation test in the evaluation of coagulation function in patients with hepatic hydatid.
Methods: The observation group consisted of 69 cases of hydatid liver patients undergoing elective combined segmenectomy, and the control group consisted of 69 healthy subjects. The correlation analysis of TEG, six coagulation items and PLT in the preoperative observation group and control group was conducted.
The impact of protein S and tissue factor pathway inhibitor on coagulation, assessed with thrombin generation, in women starting combined oral contraceptives.
Res Pract Thromb Haemost
July 2025
The Coagulation Unit, Department of Clinical Biochemistry, Aalborg University Hospital, Aalborg, Denmark.
Background: Combined oral contraceptives (COCs) are associated with an increased risk of venous thromboembolism. Several changes are induced in both coagulant and anticoagulant factors, of which the impact on protein S (PS) and tissue factor pathway inhibitor (TFPI) may be especially important. The global thrombin generation (TG) assay, which accounts for all pro- and anticoagulant factors, can be used to evaluate the effect of the changes of PS and TFPI using antibodies to eliminate the effect of these inhibitors.
View Article and Find Full Text PDFInherited thrombophilia in a Han Chinese family caused by prothrombin Ile441Met mutation.
Res Pract Thromb Haemost
July 2025
Department of Neurology, Bishan Hospital of Chongqing Medical University, Chongqing, China.
Background: Inherited thrombophilia (IT) is a genetically determined predisposition to thromboembolic events. Beyond the well-known G20210A mutation, there has been limited research on other prothrombin mutations in the Chinese population.
Objectives: This study aimed to identify and characterize a novel prothrombin mutation in a Han Chinese family with IT.
Coagulation factor XII haploinsufficiency is protective against venous thromboembolism in a population-scale multidimensional analysis.
Nat Commun
September 2025
Cardiovascular Disease Initiative, The Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Coagulation factor XII has been identified as a potential drug target that could prevent thrombosis without increasing the risk of bleeding. However, human data to support the development of factor XII-directed therapeutics are lacking. To assess the role of factor XII in venous thromboembolism, we examine genetic variation in the coding region of the F12 locus across 703,745 participants in the UK Biobank and NIH All of Us biorepositories.
View Article and Find Full Text PDF